Literature DB >> 27886404

Adipophilin expression in cutaneous malignant melanoma.

Masakazu Fujimoto1, Ibu Matsuzaki1, Yuki Yamamoto2, Akihiko Yoshizawa3, Kenji Warigaya1, Yoshifumi Iwahashi1, Fumiyoshi Kojima1, Fukumi Furukawa2, Shin-Ichi Murata1.   

Abstract

BACKGROUND: The lipogenic pathway is upregulated in cancer cells, including melanomas. However, the pathological significance of cellular lipids in melanocytic lesions has yet to be determined. In this study, we evaluated intracytoplasmic lipid droplets in melanocytic nevi (MNs) and malignant melanomas via immunohistochemical analysis of adipophilin (ADP), which coats lipid droplets.
METHODS: One hundred primary cutaneous melanocytic lesions [33 MNs, 17 melanomas in situ (MIS), and 50 invasive melanomas (IMs)] were immunostained for ADP. The intensity score (IS) and proportion score (PS) of ADP staining in each case was recorded semiquantitatively on a scale of 0 to 3+.
RESULTS: High ADP expression (IS2/3+ and PS2/3+) was observed in 27 primary cutaneous melanocytic lesions that consisted of 23 IMs, three MISs, and one MN. Consequently, high ADP expression was associated with malignancy (38.8% vs. 3.0%; p < 0.0001). Among the IMs, high ADP expression was more prevalent in pT3/4 than pT1/2 (63.3% vs. 23.8%; p = 0.01) and Stage 3/4 than Stage 1/2 (76.9% vs. 36.8%; p = 0.02).
CONCLUSIONS: The majority of the melanocytic lesions with high ADP expression were malignant melanomas in our cohort. Therefore, ADP expression may serve as a sensitive diagnostic marker for malignant melanoma.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  adipophilin; immunohistochemical analysis; malignant melanoma; melanocytic nevus

Mesh:

Substances:

Year:  2016        PMID: 27886404     DOI: 10.1111/cup.12868

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  7 in total

1.  Adipophilin expression in primary and metastatic uveal melanoma: a pilot study.

Authors:  Miltiadis Fiorentzis; Helen Kalirai; Periklis Katopodis; Sarah E Coupland
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-03-15       Impact factor: 3.117

2.  Adipophilin expression in cutaneous malignant melanoma is associated with high proliferation and poor clinical prognosis.

Authors:  Masakazu Fujimoto; Ibu Matsuzaki; Kazuchika Nishitsuji; Yuki Yamamoto; Daisuke Murakami; Takanori Yoshikawa; Ayaka Fukui; Yuuki Mori; Masaru Nishino; Yuichi Takahashi; Yoshifumi Iwahashi; Kenji Warigaya; Fumiyoshi Kojima; Masatoshi Jinnin; Shin-Ichi Murata
Journal:  Lab Invest       Date:  2019-12-19       Impact factor: 5.662

3.  Expression status and prognostic value of the perilipin family of genes in breast cancer.

Authors:  Xuede Zhang; Lei Su; Kai Sun
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

Review 4.  Lipid droplets: platforms with multiple functions in cancer hallmarks.

Authors:  André L S Cruz; Ester de A Barreto; Narayana P B Fazolini; João P B Viola; Patricia T Bozza
Journal:  Cell Death Dis       Date:  2020-02-06       Impact factor: 8.469

5.  Lipid Droplet-Related PLIN2 in CD68+ Tumor-Associated Macrophage of Oral Squamous Cell Carcinoma: Implications for Cancer Prognosis and Immunotherapy.

Authors:  Yijia He; Yuexin Dong; Xinwen Zhang; Zhuang Ding; Yuxian Song; Xiaofeng Huang; Sheng Chen; Zhiyong Wang; Yanhong Ni; Liang Ding
Journal:  Front Oncol       Date:  2022-03-15       Impact factor: 6.244

6.  Overexpression of PLIN2 is a prognostic marker and attenuates tumor progression in clear cell renal cell carcinoma.

Authors:  Qi Cao; Hailong Ruan; Keshan Wang; Zhengshuai Song; Lin Bao; Tianbo Xu; Haibing Xiao; Cheng Wang; Gong Cheng; Junwei Tong; Xiangui Meng; Di Liu; Hongmei Yang; Ke Chen; Xiaoping Zhang
Journal:  Int J Oncol       Date:  2018-04-26       Impact factor: 5.650

7.  Adipophilin expression is an independent marker for poor prognosis of patients with triple-negative breast cancer: An immunohistochemical study.

Authors:  Katsuhiro Yoshikawa; Mitsuaki Ishida; Hirotsugu Yanai; Koji Tsuta; Mitsugu Sekimoto; Tomoharu Sugie
Journal:  PLoS One       Date:  2020-11-17       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.